X

biopharmaceuticals

Ocean Biomedical (NASDAQ: OCEA) Research Summary

Ocean Biomedical, Inc. (NASDAQ: OCEA) is a preclinical biotech company focused on moving new therapeutic candidates efficiently from the laboratory…

Ocean Biomedical (NASDAQ: OCEA) Research Summary

Ocean Biomedical, Inc. (NASDAQ: OCEA) is a new-generation biotechnology firm that works to accelerate the development of new therapies by…

Biogen (BIIB) Q3 2023 Earnings: Key financials and quarterly highlights

Biogen Inc. (NASDAQ: BIIB) reported third quarter 2023 earnings results today. Total revenue rose 1% year-over-year to $2.53 billion. Revenues…

ABBV Earnings: A snapshot of AbbVie’s Q3 2023 report

Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced third-quarter 2023 financial results, reporting lower revenues and net income. The…

Ocean Biomedical’s chief scientist Dr. Jonathan Kurtis receives Falk Award for malaria drug candidate

Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its chief scientist, Jonathan Kurtis MD, PhD has received the…

Ocean Biomedical (OCEA) announces new patent for anti-fibrosis discovery

Ocean Biomedical, Inc. (NASDAQ: OCEA), a leading biopharma company that works to accelerate the development and commercialization of scientifically compelling…

Ocean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day

Biopharmaceutical company Ocean Biomedical, Inc. (NASDAQ: OCEA) provided details of its multi-pronged lung cancer program built on novel immunotherapy discoveries…

Key highlights from Abbott Laboratories (ABT) Q2 2023 earnings results

Abbott Laboratories (NYSE: ABT) reported second quarter 2023 earnings results today. Net sales decreased 11.4% year-over-year to $10 billion. Organic sales…

Infographic: Ocean Biomedical Inc. (OCEA) quarter ended September 30, 2022

Ocean Biomedical, Inc. (NASDAQ: OCEA) was formed through the combination of Aesther Healthcare Acquisition Corp. with Ocean Biomedical. Here’s a look at…

IPO Alert: What lies ahead for MAIA Biotechnology after stock listing?

The IPO market is yet to fully recover from headwinds like the economic slowdown and Russia-Ukraine war. But activity is…

ANI Pharmaceuticals, Inc. (ANIP) Q4 2021 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) Q4 2021 earnings call dated Mar. 15, 2022 Corporate Participants: Judy DiClemente -- Investor Relations Nikhil Lalwani -- President…

IPO Alert: Key facts about CinCor Pharma’s upcoming market debut

The healthcare sector, led by pharmaceutical and biotechnology firms, has contributed significantly to the IPO boom that sent the market…

Biofrontera sees TAM of $4 Bln for lead product Ameluz: CEO Erica Monaco

Caption: iStock Biofrontera Inc. (Nasdaq: BFRI) is a biopharmaceutical company providing specialty dermatology therapies and services in the United States.…